GenePOC launches its revogene(TM) instrument and GBS LB test in Canada

Québec, Canada (ots) - GenePOC Inc., member of the Debiopharm
Group(TM), is proud to announce the launch in its home market for the
revogene instrument and the GenePOC(TM) GBS LB assay.

About Group B Streptococcus (GBS) in Canada

GBS is the leading cause of infection in infants worldwide with a
fatality rate between 4-6%[1]. The SOGC guideline[2] recommends
universal antepartum screening for women at 35-37 weeks of gestation,
along with intrapartum antibiotic prophylaxis. While this has
resulted in a decrease in early onset disease (EOD) rate, there is
still an ongoing need for more sensitive GBS detection. In fact,
studies have shown that up to 61.4% of term infants with GBS disease
are born to women who have had negative cultures for Group B
Streptococcus[3].

About GenePOC GBS LB test

GenePOC GBS LB is indicated for identification of Group B
Streptococcus from LIM broth enrichments of vaginal/rectal specimen
swabs obtained from pregnant women.

"We are passionate at GenePOC about eliminating the highly
debilitating effects of EOD which include meningitis, pneumonia and
in some cases death. In launching the GBS LB assay, we are directly
addressing that unmet clinical need and meeting the market
expectations," said Patrice Allibert, PhD, CEO of GenePOC.

"A dream comes true of bringing a smart and portable device for
molecular diagnostics that can replace routine culture methods,
giving better performance and much more rapid turnaround times,"
commented Prof Dr Michel G. Bergeron, from Université Laval and
Founder of GenePOC.

About revogene(TM)

The revogene is an automated stand-alone instrument that enables
testing from single-use proprietary microfluidic cartridges, with
fluorescence-based real-time polymerase chain reaction platform to
deliver an accurate diagnosis.

About GenePOC

GenePOC, member of the Debiopharm Group(TM), specializes in
diagnostic devices for the prevention and detection of infectious
diseases. The company aims to become the market leader in the rapid
microbial testing. GenePOC's revogene instrument is also available in
the US and EU markets with a rapidly expanding test menu.

Further information: www.genepoc-diagnostics.com

[1] Edmond et al., The Lancet, 2012; 379; p.547-55]

[2] Money et al., J Obstet Gynaecol Can 2013;35(10):e1-e10]

[3] Van Dyke, et al., NEJM, June 18, 2009; 360(25):2626-36]

Pressekontakt:
Patrice Allibert, Ph.D
CEO
patrice.allibert@genepoc.ca
Tel.: +1-418-650-3535

Original-Content von: Debiopharm International SA, übermittelt durch news aktuell